MyCEI Login


Update on Inflammation, Aging, and CMV Co-Infection in Treated HIV


Published Date: 05/08/2023

Expiration Date: 04/11/2026

CE Credit: CME:1


Immune activation and chronic inflammation persist throughout the course of HIV disease and contribute to the multimorbidities that complicate the management of our patients as they age. CMV coinfection seems to be a particularly troublesome cofactor for many PLWH. Peter Hunt returns with an update on the most recent research pertinent to understanding these complexities as they relate to aging. 


Peter W. Hunt,MD

Peter Hunt’s primary research focus is on the inflammatory consequences of HIV infection. His translational research program seeks to understand the causes and consequences of persistent immune activation and its impact on aging-associated multi-morbidity and mortality in treated HIV infection, as well as its impact on HIV persistence. He also conducts clinical trials of novel immune-based interventions designed to decrease immune activation and recently completed a term as Chair of the Inflammation Committee of the AIDS Clinical Trials Group (ACTG). In July 2016, he also started a laboratory to better characterize the immune defects that drive morbidity and mortality in treated HIV, with a specific focus on the role of CMV co-infection as an important mediator. He leads a large clinical trial of the anti-CMV drug letermovir in the ACTG, exploring its impact not just on systemic inflammation, but also on cardiometabolic and neurocognitive outcomes. 

Dr. Hunt led a translational research program in Mbarara, Uganda, focused on the determinants of immune recovery during suppressive antiretroviral therapy in that setting and helped develop a large mucosal immunology program at Zuckerberg San Francisco General Hospital focused on the impact of HIV on gut-associated lymphoid tissue and the determinants of microbial translocation in HIV infection.

Learning Objectives

  • Be aware of the causes and putative consequences of persistent inflammation in treated HIV.
  • Know the current strategies being pursued to decrease immune activation and multimorbidity in treated HIV.
  • Understand the evidence suggesting that CMV may play an important role in multimorbidity in treated HIV as well as COVID-19 complications.

Continuing Education Credit Information